Decoding genetic interactions to advance cancer care

A BETTER FUTURE FOR BRAIN CANCER PATIENTS

More than 250,000 people are diagnosed with brain cancer every year.

20,000 are children under the age of 15.

Average survival 15 months.

BRAIN CANCER TREATMENT IS SIMPLISTIC AND HASN’T CHANGED FOR THE PAST 20 YEARS

We have developed a scalable genetic interaction map – the Tumour Interactome Atlas™ – that analyses cancer cells genetic interactions to inform better diagnosis and treatment.

Our GOAL

We aim to translate the insights generated by the Tumour Interactome Atlas™ into an easy-to-use application that will enable physicians to provide more precise diagnosis, and identify more effective treatment for brain cancer and beyond.

Intervance is an early-stage start-up positioned at the cutting edge of healthcare technology. Leveraging advancements in clinical genetic expression data and machine learning, our aim is to revolutionize the approach to cancer treatment. Our innovative solutions empower physicians with data-driven insights, enabling them to make more informed decisions and ultimately provide improved care for their patients. Our mission is to transform the landscape of oncology, ensuring a better future for cancer patients through the power of precision medicine.